News | January 11, 2026
Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The supplements are made using only vegetarian-sourced ingredients
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Subscribe To Our Newsletter & Stay Updated
